Survodutide

At a glance

---

What is survodutide?

Survodutide is a synthetic peptide that simultaneously activates two receptors for metabolic hormones: the glucagon receptor and the GLP-1 (glucagon-like peptide-1) receptor.^[1] This "dual agonist" design distinguishes it from semaglutide (GLP-1 only) and places it in the same family as other investigational glucagon/GLP-1 dual agonists like pemvidutide. It is given as a once-weekly subcutaneous injection.

The compound is developed by Boehringer Ingelheim under the research code BI 456906 and was originally discovered at Zealand Pharma, which licensed it to Boehringer Ingelheim for global development. Phase 2 trials reported in 2024 generated significant attention: a dose-finding obesity trial showed up to 14.9% weight loss, and a biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis) trial showed histological improvement in the majority of treated participants.^[5][4]

The key feature of survodutide is its glucagon-receptor component. Where GLP-1 agonism mainly drives appetite suppression and glucose control, glucagon-receptor agonism is thought to add hepatic fat breakdown and increased energy expenditure. This is the same biological rationale behind retatrutide, which adds glucagon agonism to a GIP/GLP-1 backbone.

---

How it works

In plain terms, survodutide mimics two hormones your body uses to regulate appetite, blood sugar, and how it stores and burns fat. By activating both the GLP-1 and glucagon pathways at once, it aims to combine appetite-driven weight loss with a more direct effect on fat in the liver and around the organs.^[1]

Think of it as working on two channels at once: one primarily affecting appetite and glucose regulation (GLP-1), and a second promoting energy expenditure and the breakdown of liver fat (glucagon). The glucagon channel is what sets survodutide apart from GLP-1-only drugs and appears to drive its standout effects on visceral and liver fat.

Detailed mechanism (for advanced readers)

Survodutide is a glucagon/GLP-1 receptor dual agonist:^[1]

GLP-1 receptor agonism:

• Glucose-dependent insulin secretion from pancreatic beta cells
• Delayed gastric emptying (contributes to satiety and to GI side effects)
• Central appetite regulation via hypothalamic and brainstem GLP-1 receptors
• This is the appetite/glycemic arm shared with semaglutide and the other GLP-1 drugs

Glucagon receptor agonism (the key differentiator):

• Promotes hepatic lipid oxidation and reduces liver fat -- the likely driver of the dramatic MASLD/MASH results
• Increases energy expenditure through thermogenesis
• Mobilizes hepatic fatty acids
• Balancing glucagon's effect on hepatic glucose production against the GLP-1 arm's glucose-lowering is a core design challenge for this drug class

Structural notes:

• Survodutide is built on a glucagon-derived peptide backbone (a glucagon analog)
• A C18 fatty-acid moiety enables albumin binding, extending half-life enough for once-weekly dosing
• The full amino-acid sequence has not been publicly disclosed by the developer; published chemical references list a molecular formula of C₁₉₂H₂₈₉N₄₇O₆₁ and CAS number 2805997-46-8

How it differs from retatrutide: Both use glucagon-receptor agonism to target liver fat. Retatrutide is a triple agonist that also activates the GIP receptor and reports higher weight loss; survodutide is a dual glucagon/GLP-1 agonist whose reported weight loss is closer to GLP-1 monotherapies but with a strong liver-fat signal.

---

What the research says

Survodutide's June 2026 data is genuinely strong on metabolic endpoints: large reductions in visceral and liver fat, liver-fat normalization in roughly 6 of 10 MASLD patients, and weight loss preferentially from fat rather than muscle. But it is still investigational -- the pivotal MASH outcome trial is ongoing, and there is no FDA approval and no confirmed filing date.

Research timeline

Survodutide has progressed from Phase 2 to two peer-reviewed Phase 3 readouts:

Human clinical trials

Survodutide has been studied in two published Phase 2 RCTs and two peer-reviewed Phase 3 RCTs, with the pivotal MASH outcome trial still ongoing:

Phase 2 program: A dose-finding obesity trial (Lancet Diabetes & Endocrinology) and a biopsy-confirmed MASH trial (NEJM) established dose-response and a safety profile, and earned the Breakthrough Therapy designation.^[5][4]

Phase 3 SYNCHRONIZE program: SYNCHRONIZE-1 (obesity, n=725) and SYNCHRONIZE-MASLD (fatty liver disease, n=218) reported in 2026. The SYNCHRONIZE-1 topline came first on April 28, 2026; the body-composition substudy and both peer-reviewed publications followed at ADA 2026 in June.^[3][1][2]

Phase 3 LIVERAGE program (ongoing): LIVERAGE evaluates survodutide in roughly 1,800 adults with MASH and F2/F3 fibrosis, with co-primary MASH-resolution and fibrosis-improvement endpoints at 52 weeks. As of June 2026, it is ongoing with no confirmed readout date.^[7]

---

What the evidence shows

Survodutide has drawn interest both as a weight-loss drug and as a potential MASH therapy. Here's what the published research tells us about the most common claims:

---

Safety & side effects

What clinical trials show

Survodutide's safety profile comes from its Phase 2 and Phase 3 trials. The overall picture is consistent with the GLP-1 receptor agonist class.^[5]

Gastrointestinal events (the most common side effects): These are dose-dependent and typically most pronounced during dose escalation:

• Nausea
• Vomiting
• Diarrhea
• Decreased appetite

In the Phase 2 obesity trial, all doses were tolerated and GI events were the most frequently reported adverse events, mostly mild to moderate and concentrated during the dose-escalation period. A slower titration schedule is used to mitigate these effects.^[5]

Other safety considerations

• Glucagon-receptor effects: Because survodutide activates the glucagon receptor, its developers must balance glucagon's tendency to raise hepatic glucose output against the glucose-lowering GLP-1 arm. Heart-rate increases and blood-pressure changes are monitored in trials, as with the broader incretin class.
• Heart rate: Modest resting heart-rate increases are a known class effect of GLP-1-based drugs and are tracked in the survodutide program.
• Unknown long-term safety: Survodutide has not been studied beyond the durations of its current trials. There is no post-marketing surveillance data, and long-term risks are not yet characterized.

What we don't know about safety

There are important gaps in the survodutide safety data:

• No long-term (multi-year) safety data: The longest reported trials run under two years. Chronic-use safety is unknown.
• No post-marketing surveillance: All data comes from controlled clinical trials. Real-world safety patterns may differ.
• Glucagon-receptor uncertainty: Chronic glucagon-receptor agonism is relatively novel. Long-term effects on hepatic glucose production, blood pressure, and other systems are not fully characterized.
• No MASH outcome data yet: The pivotal LIVERAGE trial -- which tests whether survodutide actually resolves MASH and improves fibrosis on biopsy -- is ongoing.
• Limited public detail on rare events: Class concerns such as pancreatitis, gallbladder events, and (for the GLP-1 class) thyroid C-cell signals require longer and larger datasets to characterize for survodutide specifically.

---

Legal & regulatory status

As of June 2026:

FDA status

Survodutide is not FDA-approved for any indication. It is an investigational drug in Phase 3 clinical trials.

• No approved survodutide product: It has not been found safe and effective for any condition by the FDA.
• Breakthrough Therapy designation (Sept 2024): The FDA granted survodutide Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis (stages F2-F3).^[6] This designation is meant to expedite development and review of promising therapies for serious conditions. It is not an approval and does not make the drug available by prescription.
• No confirmed filing timeline: The pivotal LIVERAGE MASH program is ongoing with no confirmed readout date, and no FDA submission date has been announced.

How to access survodutide today

The only legal way to access survodutide is through enrollment in a clinical trial. Trial listings can be found at ClinicalTrials.gov by searching "survodutide" or "BI 456906."^[7]

For the broader legal-status logic that applies to all investigational peptides, see Why Investigational Peptides Are Not Compoundable.

WADA / USADA status

Survodutide is not prohibited under the 2026 WADA Prohibited List. GLP-1 receptor agonists are on WADA's Monitoring Program rather than the Prohibited List, so their use by athletes is tracked but does not constitute an anti-doping violation. As a glucagon/GLP-1 dual agonist, survodutide is not currently prohibited, though WADA could reclassify the GLP-1 class in a future update.^[9]

---

How survodutide compares

Survodutide's natural comparators are retatrutide (a triple agonist that also uses glucagon agonism) and the GLP-1-only and GIP/GLP-1 standards. No head-to-head trials exist, so these comparisons rely on cross-trial data, which has important limitations:

The key tradeoffs:

• Weight loss: On cross-trial numbers, survodutide (~16.6%) trails tirzepatide (~20-22%) and retatrutide (~24-29%) and sits closer to GLP-1 monotherapies. But no head-to-head trials exist.^[1]
• Visceral and liver fat: Survodutide's standout feature. The glucagon component drives large reductions in visceral fat (up to 34%) and liver fat (up to 63%), and liver-fat normalization in roughly 6 of 10 MASLD patients.^[1][2]
• Cardiovascular protection: Semaglutide wins clearly -- the SELECT trial demonstrated a reduction in major adverse cardiovascular events. Survodutide has no CV outcomes data yet.
• Safety track record: Semaglutide has years of post-marketing data from millions of patients. Survodutide has data from its trial population only.
• Availability: Semaglutide is FDA-approved and available by prescription. Survodutide is not available outside clinical trials.

The bottom line: survodutide's distinctive promise is in metabolic-liver health -- visceral and liver fat -- rather than in topping the weight-loss leaderboard. Whether that translates into an approved MASH therapy depends on the ongoing LIVERAGE outcome trial.

---

Related content

Peptide

Retatrutide Profile

Eli Lilly's triple GIP/GLP-1/glucagon agonist. Like survodutide, it uses glucagon-receptor agonism to drive liver fat reduction — but adds a third (GIP) receptor and reports higher weight loss.

Peptide

Cagrilintide Profile

A long-acting amylin analog taking a different mechanistic route to weight loss — useful context for how survodutide's glucagon/GLP-1 approach compares.

Peptide

Pemvidutide Profile

Another investigational GLP-1/glucagon dual agonist in development for obesity and MASH — survodutide's closest mechanistic peer.

Guide

Why Investigational Peptides Are Not Compoundable

The legal-status logic that applies equally to survodutide: investigational drugs cannot be prescribed or compounded, and research-use vendors are not pharmacy access.

Guide

What Are Peptides?

A foundational primer — helpful context for understanding survodutide's dual-receptor mechanism.

Tool

Half-Life and Accumulation Plotter

Visualize how survodutide's once-weekly dosing accumulates over time.

---

References

1. [1]

   le Roux CW, Wharton S, Startseva E, et al.. “Survodutide Once Weekly for the Treatment of Adults with Obesity.” N Engl J Med. 2026. DOIRCT

   Pivotal Phase 3 SYNCHRONIZE-1 RCT. n=725, 76 weeks, obesity/overweight without T2D. Up to 16.6% weight loss (efficacy estimand) vs. 3.2% placebo. Prespecified MRI substudy: up to 34.0% visceral fat and 63.1% liver fat reduction with limited lean-mass loss. Published to coincide with ADA 2026 (June 7, 2026).

2. [2]

   Kaplan LM, Sanyal AJ, Newsome PN, et al.. “Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.” Nat Med. 2026. DOIRCT

   Phase 3 SYNCHRONIZE-MASLD RCT. n=218, 48 weeks, weekly 6.0 mg vs. placebo. 61.0% reached liver-fat normalization (<5%) vs. 5.7% placebo; up to 84.2% achieved ≥30% relative liver-fat reduction. Published in Nature Medicine June 8, 2026.

3. [3]

   Boehringer Ingelheim / Zealand Pharma. “Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial.” 2026. LinkRCT

   Topline press release for SYNCHRONIZE-1, announced April 28, 2026. Met co-primary (efficacy and treatment-regimen estimands) and key secondary waist-circumference endpoints. Up to 16.6% weight loss at 76 weeks vs. 3.2% placebo. Pre-dates the June 2026 peer-reviewed publication and substudy data.

4. [4]

   Sanyal AJ, Bedossa P, Fraessdorf M, et al.. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” N Engl J Med. 2024. 391(4):311-319 DOI PubMedRCT

   Phase 2 MASH trial. n=293, 48 weeks, doses 2.4/4.8/6.0 mg vs. placebo. MASH improvement without fibrosis worsening in up to 62% (4.8 mg) vs. 14% placebo; ≥1-stage fibrosis improvement in up to 36% vs. 22%; ≥30% liver-fat reduction in up to 67%. Basis for FDA Breakthrough Therapy designation.

5. [5]

   le Roux CW, Steen O, Lucas KJ, et al.. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol. 2024. 12(3):162-173 DOI PubMedRCT

   Phase 2 dose-finding obesity trial. n=387, 46 weeks. Mean weight loss up to 14.9% on 4.8 mg. Dose-dependent reductions; GI-dominant tolerability profile similar to GLP-1 class.

6. [6]

   Boehringer Ingelheim / Zealand Pharma. “Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide.” 2024. LinkReview

   Announces FDA Breakthrough Therapy designation (granted September 2024) for non-cirrhotic MASH with moderate/advanced fibrosis (F2-F3), and initiation of LIVERAGE (~1,800 adults) and LIVERAGE-Cirrhosis (~1,590 adults). Confirms Zealand Pharma licensing to Boehringer Ingelheim. Breakthrough Therapy is a development designation, NOT approval.

7. [7]

   Boehringer Ingelheim. “LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (NCT06632444).” 2026. LinkRCT

   Ongoing global Phase 3 LIVERAGE trial. ~1,800 adults with MASH and F2/F3 fibrosis, weekly survodutide up to 6 mg vs. placebo. Co-primary endpoints at 52 weeks: MASH resolution without fibrosis worsening; ≥1-stage fibrosis improvement without MASH worsening. No confirmed readout or FDA-filing date as of June 2026.

8. [8]

   American Diabetes Association. “Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health.” 2026. LinkConference abstract

   ADA 2026 Scientific Sessions (New Orleans) press release summarizing the SYNCHRONIZE-1 body-composition substudy and SYNCHRONIZE-MASLD, presented June 7-8, 2026. Confirms ~6 of 10 MASLD patients normalized liver fat at 48 weeks and preferential fat-over-lean loss.

9. [9]

   World Anti-Doping Agency. “The 2026 Prohibited List — International Standard.” 2026. Link
10. [10]

    U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

    FDA safety communication on unapproved/compounded GLP-1-class products. Contextualizes why an investigational drug like survodutide cannot be legally sold, prescribed, or compounded.

---